Evidence map›Paper›PMID 42358367›Full record

ArticleFrontiers in pharmacology2026

Pharmacological profiling of intravenous MP-04: sustained NAD

Alip Ghosh, Gautham Pranesh, Nikhil Zachariah, Eisuke Murakami, Alonso Heredia, Poonam Mathur, Leigh Ann Burns-Naas, Steve Weng, Arvind Ramanathan, Shyam Kottilil and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alip GhoshInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Gautham PraneshMitoPower, LLC, Palo Alto, CA, United States.
Nikhil ZachariahMitoPower, LLC, Palo Alto, CA, United States.
Eisuke MurakamiMitoPower, LLC, Palo Alto, CA, United States.
Alonso HerediaInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Poonam MathurInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
Leigh Ann Burns-NaasMagnolia Toxicology Consulting, Limited Liability Company, Michigan, MI, United States.
Steve WengMitoPower, LLC, Palo Alto, CA, United States.
Arvind RamanathanInstitute for Stem Cell Science and Regenerative Medicine (InStem), Bangalore, India.
Shyam KottililInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States.
G Mani SubramanianMitoPower, LLC, Palo Alto, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Systemic inflammation and mitochondrial bioenergetic failure are central drivers of multi-organ dysfunction in advanced liver disease, sepsis, and acute kidney injury (AKI). Currently available therapies remain largely supportive and fail to directly address intracellular NAD Methods: The NAD Results: MP-04 produced rapid, distinct, and dose-dependent increases in intracellular NAD Conclusion: MP-04 is a safe and highly potent intravenous NAD

Indexed as

acute kidney injury (AKI)cytokine modulationdihydronicotinamide riboside (NRH)hepatorenal syndromeimmunomodulationmitochondrial bioenergeticsNAD+ metabolismsystemic inflammation

Identifiers

PMID42358367
PMCPMC13291046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.